NovoCure Ltd. NVCR

NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...

NovoCure (NVCR) is back in focus after the company confirmed that long-serving director Timothy Scannell retired from its board on September 2, 2026, following five years of service. The modest 0.85% 1 day share price return and 3.22% 7 day share price return leave NovoCure trading at US$16.67. At the same time, a 27.06% year to date share price return and 28.23% 1 year total shareholder return contrast with a much weaker 5 year total shareholder return, suggesting recent momentum is building...